Patrick Tan

List of Publications by Year
in descending order

286 papers	24,361 citations	6613 79 h-index	9345 143 g-index
301 all docs	301 docs citations	301 times ranked	33297 citing authors

#	Article	IF	Citations
1	Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut, 2023, 72, 226-241.	12.1	6
2	Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut, 2022, 71, 676-685.	12.1	21
3	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut, 2022, 71, 1277-1288.	12.1	23
4	STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis. Gut, 2022, 71, 1515-1531.	12.1	23
5	Mapping the genomic diaspora of gastric cancer. Nature Reviews Cancer, 2022, 22, 71-84.	28.4	72
6	Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer. Cancer Discovery, 2022, 12, 670-691.	9.4	165
7	Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis. Cancer Letters, 2022, 525, 115-130.	7.2	19
8	Inflammasome-Associated Gastric Tumorigenesis Is Independent of the NLRP3 Pattern Recognition Receptor. Frontiers in Oncology, 2022, 12, 830350.	2.8	3
9	Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer. Gastric Cancer, 2022, 25, 542-557.	5.3	14
10	Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. Cancer Research, 2022, 82, 2538-2551.	0.9	7
11	Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial. Scientific Reports, 2022, 12, .	3.3	2
12	Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. Journal of Clinical Oncology, 2022, 40, 2830.	1.6	23
13	A genomicâ€augmented multivariate prognostic model for the survival of naturalâ€killer/Tâ€cell lymphoma patients from an international cohort. American Journal of Hematology, 2022, 97, 1159-1169.	4.1	4
14	Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut, 2021, 70, 1823-1832.	12.1	38
15	SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. Gastric Cancer, 2021, 24, 589-601.	5.3	12
16	CRISPRi enables isoform-specific loss-of-function screens and identification of gastric cancer-specific isoform dependencies. Genome Biology, 2021, 22, 47.	8.8	12
17	Family history assessment significantly enhances delivery of precision medicine in the genomics era. Genome Medicine, 2021, 13, 3.	8.2	19
18	Long-read transcriptome sequencing reveals abundant promoter diversity in distinct molecular subtypes of gastric cancer. Genome Biology, 2021, 22, 44.	8.8	46

#	Article	IF	Citations
19	Histone lysine methyltransferase Prâ€set7/SETD8 promotes neural stem cell reactivation. EMBO Reports, 2021, 22, e50994.	4.5	12
20	Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination. Cell Reports, 2021, 34, 108779.	6.4	64
21	â€œ3Gâ€•Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. Cancer Research, 2021, 81, 2788-2798.	0.9	9
22	Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing. Modern Pathology, 2021, 34, 1320-1332.	5.5	19
23	Variation in predicted COVIDâ€19 risk among lemurs and lorises. American Journal of Primatology, 2021, 83, e23255.	1.7	7
24	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine, 2021, 13, .	12.4	59
25	Low frequency variants associated with leukocyte telomere length in the Singapore Chinese population. Communications Biology, 2021, 4, 519.	4.4	15
26	RegAB Homolog of Burkholderia pseudomallei is the Master Regulator of Redox Control and involved in Virulence. PLoS Pathogens, 2021, 17, e1009604.	4.7	6
27	Highly recurrent CBS epimutations in gastric cancer CpG island methylator phenotypes and inflammation. Genome Biology, 2021, 22, 167.	8.8	10
28	Activation of EHF via STAT3 phosphorylation by LMP2A in Epsteinâ€Barr virusâ€“positive gastric cancer. Cancer Science, 2021, 112, 3349-3362.	3.9	16
29	Mapping genomic and epigenomic evolution in cancer ecosystems. Science, 2021, 373, 1474-1479.	12.6	38
30	The wearable activity technology and action-planning trial in cancer survivors: Physical activity maintenance post-intervention. Journal of Science and Medicine in Sport, 2021, 24, 902-907.	1.3	13
31	Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer. Genome Medicine, 2021, 13, 158.	8.2	7
32	GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics, 2021, 1, 100029.	6.5	94
33	A tumour-resident Lgr5+ stem-cell-like pool drives the establishment and progression of advanced gastric cancers. Nature Cell Biology, 2021, 23, 1299-1313.	10.3	34
34	HNF4Î± pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer. Gut, 2020, 69, 231-242.	12.1	27
35	Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. Gut, 2020, 69, 1039-1052.	12.1	36
36	Cross-species chromatin interactions drive transcriptional rewiring in Epsteinâ€“Barr virusâ€“positive gastric adenocarcinoma. Nature Genetics, 2020, 52, 919-930.	21.4	65

#	Article	IF	Citations
37	Profiling of gastric cancer cell-surface markers to achieve tumourâ€“normal discrimination. BMJ Open Gastroenterology, 2020, 7, e000452.	2.7	6
38	Genetic Studies of Hypertrophic Cardiomyopathy in Singaporeans Identify Variants in TNNI3 and TNNT2 That Are Common in Chinese Patients. Circulation Genomic and Precision Medicine, 2020, 13, 424-434.	3.6	18
39	An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood, 2020, 135, 2337-2353.	1.4	49
40	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Frontiers in Oncology, 2020, 10, 763.	2.8	32
41	Evaluation of family health history collection methods impact on data and risk assessment outcomes. Preventive Medicine Reports, 2020, 18, 101072.	1.8	7
42	Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing Î²1 Integrin, Enhancing Drug Resistance. Cancer Research, 2020, 80, 3222-3235.	0.9	94
43	A tumor-associated splice-isoform of MAP2K7 drives dedifferentiation in MBNL1-low cancers via JNK activation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16391-16400.	7.1	23
44	DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia. Gut, 2020, 69, 1738-1749.	12.1	11
45	Enabling Technologies for Personalized and Precision Medicine. Trends in Biotechnology, 2020, 38, 497-518.	9.3	169
46	Genomic basis for RNA alterations in cancer. Nature, 2020, 578, 129-136.	27.8	280
47	AQP5 enriches for stem cells and cancer origins in the distal stomach. Nature, 2020, 578, 437-443.	27.8	89
48	An LCM-based genomic analysis of SPEM, Gastric Cancer and Pyloric Gland Adenoma in an Asian cohort. Modern Pathology, 2020, 33, 2075-2086.	5.5	6
49	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. JCO Global Oncology, 2020, 6, 628-638.	1.8	35
50	A functional network of gastric-cancer-associated splicing events controlled by dysregulated splicing factors. NAR Genomics and Bioinformatics, 2020, 2, lqaa013.	3.2	5
51	Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. Journal of Clinical Investigation, 2020, 130, 3005-3020.	8.2	12
52	Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. Journal of Clinical Investigation, 2020, 130, 5833-5846.	8.2	58
53	IDDF2020-ABS-0215â€…Enhancer reprogramming by selective HDAC8 inhibition potentiates tumor remission and durable benefit by PD-L1 blockade. , 2020, , .		0
54	New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer, 2019, 22, 77-90.	5.3	41

#	Article	IF	Citations
55	Population genomics in South East Asia captures unexpectedly high carrier frequency for treatable inherited disorders. Genetics in Medicine, 2019, 21, 207-212.	2.4	18
56	Genomic characterisation of breast fibroepithelial lesions in an international cohort. Journal of Pathology, 2019, 249, 447-460.	4.5	33
57	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. Cell, 2019, 179, 736-749.e15.	28.9	126
58	Digital phenotyping by consumer wearables identifies sleep-associated markers of cardiovascular disease risk and biological aging. Communications Biology, 2019, 2, 361.	4.4	34
59	Dissection of gastric cancer heterogeneity for precision oncology. Cancer Science, 2019, 110, 3405-3414.	3.9	65
60	A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters. Cell, 2019, 178, 1465-1477.e17.	28.9	144
61	Implementation of genomics in medical practice to deliver precision medicine for an Asian population. Npj Genomic Medicine, 2019, 4, 12.	3.8	17
62	WHOLE-GENOME SEQUENCING REVEALS IMMUNOTHERAPEUTIC OPTIONS FOR NATURAL-KILLER/T CELL LYMPHOMA PATIENTS. Hematological Oncology, 2019, 37, 203-204.	1.7	0
63	Promoting physical activity in regional and remote cancer survivors (PPARCS) using wearables and health coaching: randomised controlled trial protocol. BMJ Open, 2019, 9, e028369.	1.9	11
64	KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study. Gastric Cancer, 2019, 22, 1193-1203.	5.3	16
65	Longâ€term outcomes of surgical management of rectal prolapse. ANZ Journal of Surgery, 2019, 89, E231-E235.	0.7	7
66	The Integrator Complex Prevents Dedifferentiation of Intermediate Neural Progenitors back into Neural Stem Cells. Cell Reports, 2019, 27, 987-996.e3.	6.4	21
67	A randomized controlled trial of WATAAP to promote physical activity in colorectal and endometrial cancer survivors. Psycho-Oncology, 2019, 28, 1420-1429.	2.3	40
68	Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene, 2019, 38, 4887-4901.	5.9	205
69	CSIG-03. STAT3-BASED PATIENT STRATIFICATION IN PRECISION NEURO-ONCOLOGY. Neuro-Oncology, 2019, 21, vi44-vi44.	1.2	0
70	Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. Journal of Cancer, 2019, 10, 5130-5138.	2.5	1
71	DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 2019, 123, 48-57.	2.8	5
72	Harnessing technology and molecular analysis to understand the development of cardiovascular diseases in Asia: a prospective cohort study (SingHEART). BMC Cardiovascular Disorders, 2019, 19, 259.	1.7	12

#	Article	IF	Citations
73	Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nature Communications, 2019, 10, 335.	12.8	77
74	Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals of Oncology, 2019, 30, 424-430.	1.2	44
75	Tollâ€like receptor 2 regulates metabolic reprogramming in gastric cancer via superoxide dismutase 2. International Journal of Cancer, 2019, 144, 3056-3069.	5.1	37
76	KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status. Pathology and Oncology Research, 2019, 25, 333-340.	1.9	29
77	A rare case of acute presentation of trocar site hernia from robot-assisted laparoscopic partial nephrectomy. Journal of Robotic Surgery, 2019, 13, 159-162.	1.8	1
78	Epigenetic alternate promoter utilization and association with PD-L1 expression in Epsteinâ€“Barr virus positive gastric cancer.. Journal of Clinical Oncology, 2019, 37, e15509-e15509.	1.6	1
79	Single-cell analysis of immune-microenvironment and immune-tumor interaction in human gastric cancers.. Journal of Clinical Oncology, 2019, 37, 29-29.	1.6	3
80	DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 43-43.	1.6	1
81	Metagenomic discovery of a distinct inflammatory subtype of human angiosarcoma associated with human herpesvirus 7.. Journal of Clinical Oncology, 2019, 37, 11047-11047.	1.6	0
82	Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers. Nature Communications, 2018, 9, 1520.	12.8	109
83	Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. Cancer Cell, 2018, 33, 137-150.e5.	16.8	175
84	Clinical Utility of a STAT3-Regulated miRNA-200 Family Signature with Prognostic Potential in Early Gastric Cancer. Clinical Cancer Research, 2018, 24, 1459-1472.	7.0	46
85	Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards?. Cancer Discovery, 2018, 8, 14-16.	9.4	10
86	HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis. Nature Communications, 2018, 9, 100.	12.8	38
87	An ancillary biomarker study in the SAMIT randomized trial: Sequential paclitaxel followed by UFT or S-1 versus UFT or S-1 alone as adjuvant chemotherapy for T4a/b gastric cancer. Annals of Cancer Research and Therapy, 2018, 26, 39-42.	0.3	1
88	Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis. Annals of Surgery, 2018, 267, 114-121.	4.2	15
89	Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. Cancer Letters, 2018, 412, 208-215.	7.2	10
90	Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. British Journal of Surgery, 2018, 105, 159-167.	0.3	199

#	Article	IF	Citations
91	Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3Î². Molecular Cancer Therapeutics, 2018, 17, 232-242.	4.1	42
92	IDDF2018-ABS-0153â€…Super-enhancer-associated master transcriptional circuitry in nafld-hcc development. , 2018, , .		0
93	A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Annals of Oncology, 2018, 29, 2356-2362.	1.2	32
94	Germline Pathogenic Variants in Homologous Recombination and DNA Repair Genes in an Asian Cohort of Young-Onset Colorectal Cancer. JNCI Cancer Spectrum, 2018, 2, pky054.	2.9	21
95	Anal squamous cell carcinoma: are we improving outcomes?. ANZ Journal of Surgery, 2018, 88, 1013-1016.	0.7	4
96	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept â€œ3Gâ€•Trial. Clinical Cancer Research, 2018, 24, 5272-5281.	7.0	20
97	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	12.6	134
98	The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. International Journal of Molecular Sciences, 2018, 19, 2079.	4.1	26
99	Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Scientific Reports, 2018, 8, 12248.	3.3	72
100	Wearable Activity Technology And Action-Planning (WATAAP) to promote physical activity in cancer survivors: Randomised controlled trial protocol. International Journal of Clinical and Health Psychology, 2018, 18, 124-132.	5.1	25
101	Transcriptional analysis of immune genes in Epsteinâ€“Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer, 2018, 21, 1064-1070.	5.3	25
102	Beyond fitness tracking: The use of consumer-grade wearable data from normal volunteers in cardiovascular and lipidomics research. PLoS Biology, 2018, 16, e2004285.	5.6	57
103	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.. Journal of Clinical Oncology, 2018, 36, e16024-e16024.	1.6	0
104	Genomics of worms, with an emphasis on Opisthorchis viverrini â€” opportunities for fundamental discovery and biomedical outcomes. Parasitology International, 2017, 66, 341-345.	1.3	7
105	Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Scientific Reports, 2017, 7, 40737.	3.3	62
106	Multiregion ultraâ€deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer. Molecular Oncology, 2017, 11, 124-139.	4.6	38
107	Molecular Genetics of Renal Cell Carcinoma. , 2017, , 83-103.		1
108	Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Science Translational Medicine, 2017, 9, .	12.4	165

#	Article	IF	Citations
109	Prognostic RNAs in oesophageal squamous cell carcinoma: small is beautiful. Gut, 2017, 66, 210-211.	12.1	1
110	Mitochondrial genomic comparison of Clonorchis sinensis from South Korea with other isolates of this species. Infection, Genetics and Evolution, 2017, 51, 160-166.	2.3	13
111	Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. Gastroenterology, 2017, 153, 191-204.e16.	1.3	158
112	Molecular subtypes in cancers of the gastrointestinal tract. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 333-342.	17.8	99
113	Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer. Oncogene, 2017, 36, 5134-5144.	5.9	56
114	A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer. Cancer Letters, 2017, 403, 13-20.	7.2	16
115	How to stomach an epigenetic insult: the gastric cancer epigenome. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 467-478.	17.8	126
116	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651.	9.4	48
117	Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Science Translational Medicine, 2017, 9, .	12.4	272
118	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clinical Cancer Research, 2017, 23, 7543-7549.	7.0	12
119	Germline Mutations in Cancer Predisposition Genes are Frequent in Sporadic Sarcomas. Scientific Reports, 2017, 7, 10660.	3.3	52
120	VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1284-1305.	9.4	111
121	Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nature Communications, 2017, 8, 435.	12.8	75
122	Misregulation of Histone Methylation Regulators in Cancer. Cancer Drug Discovery and Development, 2017, , 221-248.	0.4	2
123	Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. Genome Research, 2017, 27, 1475-1486.	5.5	90
124	Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc. Stem Cells, 2017, 35, 2027-2036.	3.2	41
125	An intrinsic mechanism controls reactivation of neural stem cells by spindle matrix proteins. Nature Communications, 2017, 8, 122.	12.8	25
126	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discovery, 2017, 7, 1116-1135.	9.4	637

#	Article	IF	Citations
127	Tiefe molekulare Characterisierung des Cholangiokarzinoms. , 2017, 55, .		0
128	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. Gastroenterology, 2016, 151, 637-650.e10.	1.3	127
129	Current perspectives toward the identification of key players in gastric cancer micro<scp>RNA</scp> dysregulation. International Journal of Cancer, 2016, 138, 1337-1349.	5.1	31
130	CXCL12/CXCR4 activation by cancerâ€associated fibroblasts promotes integrin Î²1 clustering and invasiveness in gastric cancer. International Journal of Cancer, 2016, 138, 1207-1219.	5.1	144
131	Distinct Responses of Stem Cells to Telomere Uncappingâ€"A Potential Strategy to Improve the Safety of Cell Therapy. Stem Cells, 2016, 34, 2471-2484.	3.2	22
132	Integrated Molecular Profiling of Human Gastric Cancer Identifies DDR2 as a Potential Regulator of Peritoneal Dissemination. Scientific Reports, 2016, 6, 22371.	3.3	58
133	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Scientific Reports, 2016, 6, 19552.	3.3	26
134	Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002). Clinical Oncology, 2016, 28, e45-e51.	1.4	6
135	Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine, 2016, 8, 195-202.	6.1	94
136	Epigenomic Consequences of Coding and Noncoding Driver Mutations. Trends in Cancer, 2016, 2, 585-605.	7.4	8
137	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open, 2016, 1, e000009.	4.5	16
138	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nature Communications, 2016, 7, 12983.	12.8	123
139	Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer. Journal of Molecular Diagnostics, 2016, 18, 416-424.	2.8	11
140	Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer. Cellular Oncology (Dordrecht), 2016, 39, 175-186.	4.4	22
141	Development of a Comprehensive Sequencing Assay for Inherited Cardiac Condition Genes. Journal of Cardiovascular Translational Research, 2016, 9, 3-11.	2.4	80
142	Defining the Molecular Alterations of Ampullary Carcinoma. Cancer Cell, 2016, 29, 135-136.	16.8	7
143	JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia, 2016, 30, 1311-1319.	7.2	130
144	Molecular classification of gastric cancer. Annals of Oncology, 2016, 27, 763-769.	1.2	215

#	Article	IF	Citations
145	Translating gastric cancer genomics into targeted therapies. Critical Reviews in Oncology/Hematology, 2016, 100, 141-146.	4.4	52
146	RUNX3 is a novel negative regulator of oncogenic TEADâ€“YAP complex in gastric cancer. Oncogene, 2016, 35, 2664-2674.	5.9	74
147	SETD2histone modifier loss in aggressive GI stromal tumours. Gut, 2016, 65, 1960-1972.	12.1	49
148	Abundant copy-number loss of CYCLOPS and STOP genes in gastric adenocarcinoma. Gastric Cancer, 2016, 19, 453-465.	5.3	9
149	Comparative Transcriptomic Exploration Reveals Unique Molecular Adaptations of Neuropathogenic Trichobilharzia to Invade and Parasitize Its Avian Definitive Host. PLoS Neglected Tropical Diseases, 2016, 10, e0004406.	3.0	25
150	CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric cancer. Oncotarget, 2016, 7, 55290-55301.	1.8	17
151	Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A. Oncotarget, 2016, 7, 6693-6710.	1.8	12
152	Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma. Oncotarget, 2016, 7, 25391-25407.	1.8	13
153	Exploring molecular variation in Schistosoma japonicum in China. Scientific Reports, 2015, 5, 17345.	3.3	33
154	MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations. Scientific Reports, 2015, 5, 13321.	3.3	113
155	Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer, 2015, 15, 762.	2.6	38
156	Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Medicine, 2015, 7, 98.	8.2	74
157	An integrative approach identified genes associated with drug response in gastric cancer. Carcinogenesis, 2015, 36, 441-451.	2.8	15
158	Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity. Cell Reports, 2015, 12, 272-285.	6.4	112
159	Upregulated, 7q21â€“22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. Cellular Signalling, 2015, 27, 1075-1086.	3.6	10
160	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut, 2015, 64, 1721-1731.	12.1	197
161	Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas. European Urology, 2015, 68, 77-83.	1.9	56
162	Genetic blueprint of the zoonotic pathogen Toxocara canis. Nature Communications, 2015, 6, 6145.	12.8	103

#	Article	IF	Citations
163	Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 233-244.	2.4	34
164	Technical Reproducibility of Single-Nucleotide and Size-Based DNA Biomarker Assessment Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 242-250.	2.8	8
165	Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology, 2015, 149, 1153-1162.e3.	1.3	355
166	OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer. Gut, 2015, 64, 37-48.	12.1	55
167	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 2015, 21, 449-456.	30.7	1,592
168	High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. Genome Biology, 2015, 16, 32.	8.8	42
169	Genomic landscapes of breast fibroepithelial tumors. Nature Genetics, 2015, 47, 1341-1345.	21.4	167
170	Fanconi anemia gene variants in therapy-related myeloid neoplasms. Blood Cancer Journal, 2015, 5, e323-e323.	6.2	32
171	Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Medicine, 2015, 7, 38.	8.2	87
172	Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. Clinical Cancer Research, 2015, 21, 870-881.	7.0	303
173	Burkholderia pseudomallei sequencing identifies genomic clades with distinct recombination, accessory, and epigenetic profiles. Genome Research, 2015, 25, 129-141.	5.5	61
174	Regulatory crosstalk between lineage-survival oncogenesKLF5, GATA4andGATA6cooperatively promotes gastric cancer development. Gut, 2015, 64, 707-719.	12.1	148
175	TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. Oncotarget, 2015, 6, 7727-7740.	1.8	51
176	Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery. PLoS ONE, 2014, 9, e90133.	2.5	96
177	Massively Parallel Sequencing of Patients with Intellectual Disability, Congenital Anomalies and/or Autism Spectrum Disorders with a Targeted Gene Panel. PLoS ONE, 2014, 9, e93409.	2.5	35
178	A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response. Clinical Cancer Research, 2014, 20, 2761-2772.	7.0	60
179	Transcriptional profiles of Burkholderia pseudomallei reveal the direct and indirect roles of Sigma E under oxidative stress conditions. BMC Genomics, 2014, 15, 787.	2.8	20
180	STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. Cell Research, 2014, 24, 1387-1402.	12.0	164

#	Article	IF	Citations
181	Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. British Journal of Cancer, 2014, 110, 1525-1534.	6.4	56
182	The Opisthorchis viverrini genome provides insights into life in the bile duct. Nature Communications, 2014, 5, 4378.	12.8	144
183	Intertumor heterogeneity of nonâ€smallâ€cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. International Journal of Cancer, 2014, 135, 1092-1100.	5.1	41
184	Whole-Genome Sequencing of Asian Lung Cancers: Second-Hand Smoke Unlikely to Be Responsible for Higher Incidence of Lung Cancer among Asian Never-Smokers. Cancer Research, 2014, 74, 6071-6081.	0.9	40
185	Unmet needs and challenges in gastric cancer: The way forward. Cancer Treatment Reviews, 2014, 40, 692-700.	7.7	156
186	Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Medicine, 2014, 6, 24.	8.2	75
187	Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. Cancer Letters, 2014, 353, 167-175.	7.2	50
188	Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nature Genetics, 2014, 46, 877-880.	21.4	172
189	Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nature Communications, 2014, 5, 4361.	12.8	72
190	RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells. Oncogene, 2014, 33, 1527-1537.	5.9	29
191	Stratification and delineation of gastric cancer signaling by in vitro transcription factor activity profiling and integrative genomics. Cellular Signalling, 2014, 26, 880-894.	3.6	11
192	The prognostic impact of KRAS mutation in colorectal cancer patients: A meta-analysis of phase III clinical trials.. Journal of Clinical Oncology, 2014, 32, e14515-e14515.	1.6	1
193	Potential predictive markers of chemotherapy for advanced gastric cancer: Biomarker study in GC0301/TOP-002, randomized phase III study of irinotecan plus S-1 versus S-1.. Journal of Clinical Oncology, 2014, 32, 55-55.	1.6	0
194	SOX7 is down-regulated in lung cancer. Journal of Experimental and Clinical Cancer Research, 2013, 32, 17.	8.6	56
195	Gastric Cancer Pathology and Underlying Molecular Mechanisms. Digestive Surgery, 2013, 30, 150-158.	1.2	79
196	KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. British Journal of Cancer, 2013, 108, 1495-1501.	6.4	76
197	Exome sequencing identifies distinct mutational patterns in liver flukeâ€"related and non-infection-related bile duct cancers. Nature Genetics, 2013, 45, 1474-1478.	21.4	426
198	Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool. Science Translational Medicine, 2013, 5, 197ra101.	12.4	233

#	Article	IF	Citations
199	Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil. Gastroenterology, 2013, 145, 554-565.	1.3	381
200	Molecular cytogenetics: recent developments and applications in cancer. Clinical Genetics, 2013, 84, 315-325.	2.0	26
201	Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut, 2013, 62, 1100-1111.	12.1	139
202	Less Is More: Burkholderia pseudomallei and Chronic Melioidosis. MBio, 2013, 4, e00709-13.	4.1	14
203	Evolutionary Analysis of Burkholderia pseudomallei Identifies Putative Novel Virulence Genes, Including a Microbial Regulator of Host Cell Autophagy. Journal of Bacteriology, 2013, 195, 5487-5498.	2.2	16
204	The Condition-Dependent Transcriptional Landscape of Burkholderia pseudomallei. PLoS Genetics, 2013, 9, e1003795.	3.5	81
205	Integrated epigenomics identifiesBMP4as a modulator of cisplatin sensitivity in gastric cancer. Gut, 2013, 62, 22-33.	12.1	88
206	Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6109-6114.	7.1	59
207	Protection against Experimental Melioidosis following Immunization with Live Burkholderia thailandensis Expressing amanno-Heptose Capsule. Vaccine Journal, 2013, 20, 1041-1047.	3.1	35
208	mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. Journal of Clinical Investigation, 2013, 123, 767-81.	8.2	89
209	Using Genomic Biomarkers to Predict Patient Prognosis and Treatment Response in Gastric Cancer. , 2013, , 105-136.		1
210	Janus Kinase 3â€“Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discovery, 2012, 2, 591-597.	9.4	236
211	TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). Clinical Cancer Research, 2012, 18, 4201-4212.	7.0	65
212	STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation. Cancer Cell, 2012, 22, 466-478.	16.8	245
213	Methylation Subtypes and Large-Scale Epigenetic Alterations in Gastric Cancer. Science Translational Medicine, 2012, 4, 156ra140.	12.4	163
214	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut, 2012, 61, 673-684.	12.1	562
215	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine, 2012, 18, 521-528.	30.7	510
216	Understanding the genetic basis of gastric cancer: recent advances. Expert Review of Gastroenterology and Hepatology, 2012, 6, 335-341.	3.0	35

#	Article	IF	Citations
217	Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nature Genetics, 2012, 44, 570-574.	21.4	560
218	Exome sequencing of liver flukeâ€“associated cholangiocarcinoma. Nature Genetics, 2012, 44, 690-693.	21.4	412
219	Modulation of C aenorhabditis elegans infection sensitivity by the LIN â€7 cell junction protein. Cellular Microbiology, 2012, 14, 1584-1599.	2.1	3
220	Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification. Breast Cancer Research and Treatment, 2012, 132, 143-151.	2.5	28
221	Development and Validation of Burkholderia pseudomallei-Specific Real-Time PCR Assays for Clinical, Environmental or Forensic Detection Applications. PLoS ONE, 2012, 7, e37723.	2.5	50
222	Toll-like receptor 2: therapeutic target for gastric carcinogenesis. Oncotarget, 2012, 3, 1260-1261.	1.8	7
223	Workshop on Treatment of and Postexposure Prophylaxis forBurkholderia pseudomalleiandB. malleiInfection, 2010. Emerging Infectious Diseases, 2012, 18, e2-e2.	4.3	170
224	An 18-gene signature (ColoPrintÂ®) for colon cancer prognosis. Nature Reviews Clinical Oncology, 2011, 8, 131-133.	27.6	67
225	Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology, 2011, 141, 476-485.e11.	1.3	304
226	CD44-SLC1A2 Gene Fusions in Gastric Cancer. Science Translational Medicine, 2011, 3, 77ra30.	12.4	54
227	A Burkholderia pseudomallei Toxin Inhibits Helicase Activity of Translation Factor eIF4A. Science, 2011, 334, 821-824.	12.6	107
228	Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17165-17170.	7.1	98
229	Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. Breast Cancer Research and Treatment, 2011, 129, 319-329.	2.5	45
230	The molecular pathogenesis of STAT3â€driven gastric tumourigenesis in mice is independent of ILâ€17. Journal of Pathology, 2011, 225, 255-264.	4.5	27
231	Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma. Clinical Cancer Research, 2011, 17, 3542-3550.	7.0	65
232	Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing. Cancer Research, 2011, 71, 29-39.	0.9	74
233	Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer. Cancer Research, 2011, 71, 3447-3452.	0.9	296
234	Genomic Loss ofmiR-486Regulates Tumor Progression and theOLFM4Antiapoptotic Factor in Gastric Cancer. Clinical Cancer Research, 2011, 17, 2657-2667.	7.0	200

#	Article	IF	Citations
235	A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures. PLoS Genetics, 2011, 7, e1002415.	3.5	42
236	Assessing Matched Normal and Tumor Pairs in Next-Generation Sequencing Studies. PLoS ONE, 2011, 6, e17810.	2.5	7
237	Validation of the AJCC staging system (7th edition) in Asian patients with localized prostate cancer undergoing radical radiotherapy.. Journal of Clinical Oncology, 2011, 29, 112-112.	1.6	0
238	Continuing Evolution of Burkholderia mallei Through Genome Reduction and Large-Scale Rearrangements. Genome Biology and Evolution, 2010, 2, 102-116.	2.5	106
239	Molecular-assisted immunohistochemical optimization. Acta Histochemica, 2010, 112, 519-528.	1.8	5
240	Identification of a regulatory cascade controlling Type III Secretion System 3 gene expression in Burkholderia pseudomallei. Molecular Microbiology, 2010, 76, 677-689.	2.5	46
241	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine, 2010, 16, 793-798.	30.7	436
242	Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers. American Journal of Surgical Pathology, 2010, 34, 956-964.	3.7	98
243	A Genomic Survey of Positive Selection in Burkholderia pseudomallei Provides Insights into the Evolution of Accidental Virulence. PLoS Pathogens, 2010, 6, e1000845.	4.7	116
244	Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Modern Pathology, 2010, 23, 123-133.	5.5	209
245	Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. Journal of Hepatology, 2010, 53, 57-66.	3.7	212
246	Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates. Genome Biology, 2010, 11, R89.	9.6	70
247	Divide and Conquer: Progress in the Molecular Stratification of Cancer. Yonsei Medical Journal, 2009, 50, 464.	2.2	4
248	Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection. Cancer Research, 2009, 69, 1055-1062.	0.9	48
249	Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. PLoS Genetics, 2009, 5, e1000676.	3.5	354
250	Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2009, 4, 12-21.	1.1	75
251	Phylogeographic reconstruction of a bacterial species with high levels of lateral gene transfer. BMC Biology, 2009, 7, 78.	3.8	155
252	Genomic and Proteomic Advances in Gastric Cancer. , 2009, , 285-321.		0

#	Article	IF	Citations
253	Use of peripheral blood genomic markers whose expression levels reflect that of breast tumor genomic markers to predict drug treatment and sensitivity. Journal of Clinical Oncology, 2009, 27, 3588-3588.	1.6	0
254	Germline polymorphisms as modulators of cancer phenotypes. BMC Medicine, 2008, 6, 27.	5.5	6
255	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. Science, 2008, 322, 1695-1699.	12.6	995
256	Novel Breast Cancer Biomarkers Identified by Integrative Proteomic and Gene Expression Mapping. Journal of Proteome Research, 2008, 7, 1518-1528.	3.7	48
257	Profiling MicroRNA Expression in Hepatocellular Carcinoma Reveals MicroRNA-224 Up-regulation and Apoptosis Inhibitor-5 as a MicroRNA-224-specific Target. Journal of Biological Chemistry, 2008, 283, 13205-13215.	3.4	341
258	A Comparative Synteny Map of Burkholderia Species Links Large-Scale Genome Rearrangements to Fine-Scale Nucleotide Variation in Prokaryotes. Molecular Biology and Evolution, 2008, 25, 549-558.	8.9	23
259	The Core and Accessory Genomes of Burkholderia pseudomallei: Implications for Human Melioidosis. PLoS Pathogens, 2008, 4, e1000178.	4.7	71
260	Inhibition of Gastric Cancer Invasion and Metastasis by PLA2G2A, a Novel Î²-Catenin/TCF Target Gene. Cancer Research, 2008, 68, 4277-4286.	0.9	103
261	Integrative Genomics IdentifiesRAB23as an Invasion Mediator Gene in Diffuse-Type Gastric Cancer. Cancer Research, 2008, 68, 4623-4630.	0.9	93
262	Clinical Validation of a Customized Multiple Signature Microarray for Breast Cancer. Clinical Cancer Research, 2008, 14, 461-469.	7.0	14
263	Management of Accidental Laboratory Exposure toBurkholderia pseudomalleiandB. mallei. Emerging Infectious Diseases, 2008, 14, e2-e2.	4.3	140
264	An Alternative Approach to Determining Therapeutic Choices in Advanced Non-small Cell Lung Carcinoma (NSCLC): Maximizing the Diagnostic Procedure and the Use of Low-Volume Lung Biopsies. Journal of Thoracic Oncology, 2007, 2, 387-396.	1.1	17
265	Molecular Diagnostics in Advanced NSCLC: Trying to Maximize a Non-Ideal Situation. Journal of Thoracic Oncology, 2007, 2, 782.	1.1	1
266	Targets of genome copy number reduction in primary breast cancers identified by integrative genomics. Genes Chromosomes and Cancer, 2007, 46, 288-301.	2.8	35
267	Quantitative Profiling of Drug-Associated Proteomic Alterations by Combined 2-Nitrobenzenesulfenyl Chloride (NBS) Isotope Labeling and 2DE/MS Identification. Journal of Proteome Research, 2006, 5, 2194-2206.	3.7	40
268	Genomic patterns of pathogen evolution revealed by comparison of Burkholderia pseudomallei, the causative agent of melioidosis, to avirulent Burkholderia thailandensis. BMC Microbiology, 2006, 6, 46.	3.3	158
269	Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer. Cancer Research, 2006, 66, 232-241.	0.9	83
270	Global Map of Growth-Regulated Gene Expression in Burkholderia pseudomallei , the Causative Agent of Melioidosis. Journal of Bacteriology, 2006, 188, 8178-8188.	2.2	40

#	Article	IF	Citations
271	A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptorâ€“Positive Tumors. Clinical Cancer Research, 2006, 12, 3288-3296.	7.0	40
272	Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Modern Pathology, 2005, 18, 374-381.	5.5	112
273	Integrative Genomic, Transcriptional, and Proteomic Diversity in Natural Isolates of the Human PathogenBurkholderia pseudomallei. Journal of Bacteriology, 2005, 187, 4276-4285.	2.2	35
274	Evidence for Selective Expression of the p53 Codon 72 Polymorphs: Implications in Cancer Development. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2245-2252.	2.5	63
275	A Molecular Signature of the Nottingham Prognostic Index in Breast Cancer. Cancer Research, 2004, 64, 2962-2968.	0.9	63
276	Patterns of large-scale genomic variation in virulent and avirulent Burkholderia species. Genome Research, 2004, 14, 2295-2307.	5.5	60
277	Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations. Clinical Cancer Research, 2004, 10, 5508-5517.	7.0	112
278	IDENTIFYING PATTERNS OF DNA FOR TUMOR DIAGNOSIS USING CAPILLARY ELECTROPHORESIS-AMPLIFIED FRAGMENT LENGTH POLYMORPHISM (CE-AFLP) SCREENING. Journal of Bioinformatics and Computational Biology, 2004, 02, 569-587.	0.8	6
279	Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Human Molecular Genetics, 2003, 12, 3245-3258.	2.9	44
280	A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Research, 2003, 63, 3309-16.	0.9	106
281	Feasibility of using low-volume tissue samples for gene expression profiling of advanced non-small cell lung cancers. Clinical Cancer Research, 2003, 9, 5980-7.	7.0	27
282	The use of animal infection models to study the pathogenesis of melioidosis and glanders. Trends in Microbiology, 2002, 10, 484-485.	7.7	3
283	Characterization of Burkholderia pseudomallei infection and identification of novel virulence factors using a Caenorhabditis elegans host system. Molecular Microbiology, 2002, 44, 1185-1197.	2.5	99
284	"Fluorescent Timer": Protein That Changes Color with Time. Science, 2000, 290, 1585-1588.	12.6	347
285	Finding Bile Duct Injuries Using Record Linkage. Journal of Clinical Epidemiology, 1999, 52, 893-901.	5.0	24
286	Complications of Cholecystectomy: Risks of the Laparoscopic Approach and Protective Effects of Operative Cholangiography. Annals of Surgery, 1999, 229, 449-457.	4.2	456